🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “Inhibrx Biosciences” Clear

  1. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  3. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  4. Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DEXAMETHASONE , Temodal 180 mg hard capsules, Temodal 5 mg hard capsules, Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Temodal 20 mg hard capsules, Temodal 250 mg hard capsules

    Inhibrx Biosciences

    Advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  5. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  7. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  8. INBRX-101/rhAAT-Fc

    Inhibrx Biosciences

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  9. INBRX-105 - PDL1x41BB antibody

    Inhibrx Biosciences

    Metastatic Solid Tumors

    phase 1 small molecule terminated

    1 trial

  10. INBRX-109

    Inhibrx Biosciences

    Ewing Sarcoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources